Plasma glial fibrillary acidic protein is an early marker of A β pathology in Alzheimer's disease

Joana B. Pereira^{1,2}, Shorena Janelidze², Ruben Smith^{2,3}, Niklas Mattsson-Carlsson^{2,3,4}, Sebastian Palmqvist^{1,3}, Henrik Zetterberg^{6,7,8,9}, Erik Stomrud^{2,5}, Nicholas J. Ashton^{6,10,11,12}, Kaj Blennow^{6,7}, Oskar Hansson^{2,5}

Abstract

Although recent clinical trials targeting amyloid- β (A β) in Alzheimer's disease (AD) have shown promising results, there is increasing evidence suggesting that understanding alternative disease pathways that interact with A β metabolism and amyloid pathology might be important to halt the clinical deterioration. In particular, there is evidence supporting a critical role of astroglial activation and astrogliosis in AD. However, to this date, no studies have assessed whether astrogliosis is independently related to A β or tau pathology, respectively, *in vivo*. To address this question, we determined the levels of the astrocytic marker glial fibrillary acidic protein (GFAP) in plasma and cerebrospinal fluid (CSF) of 217 A β -negative cognitively unimpaired individuals, 71 A β -positive cognitively unimpaired individuals, 78 A β -positive cognitively impaired individuals, 63 A β -negative cognitively impaired individuals and 75 patients with a non-AD neurodegenerative disorder from the Swedish BioFINDER-2 study. Subjects underwent longitudinal A β (¹⁸F-flutemetamol) and tau (¹⁸F-RO948) positron emission tomography (PET) as well as cognitive testing. We found that plasma GFAP concentration was significantly increased in all A β -positive groups compared with subjects without A β pathology ($p < 0.01$). In addition, there were significant associations between plasma GFAP with higher A β -PET signal in all A β -positive groups, but also in cognitively normal individuals with normal A β values ($p < 0.001$), which remained significant after controlling for tau-PET signal. Furthermore, plasma GFAP could predict A β -PET positivity with an area under the curve of 0.76, which was greater than the performance achieved by CSF GFAP (0.69) and other glial markers (CSF YKL-40: 0.64, sTREM2: 0.71). Although correlations were also observed between tau-PET and plasma GFAP, these were no longer significant after controlling for A β -PET. In contrast to plasma GFAP, CSF GFAP concentration was significantly increased in non-AD patients compared to other groups ($p < 0.05$) and correlated with A β -PET only

in A β -positive cognitively impaired individuals ($p=0.005$). Finally, plasma GFAP was associated with both longitudinal A β -PET and cognitive decline, and mediated the effect of A β -PET on tau-PET burden, suggesting that astrocytosis secondary to A β aggregation might promote tau accumulation. Altogether, these findings indicate that plasma GFAP is an early marker associated with brain A β pathology but not tau aggregation, even in cognitively normal individuals with a normal A β status. This suggests that plasma GFAP should be incorporated in current hypothetical models of AD pathogenesis and be used as a non-invasive and accessible tool to detect early astrocytosis secondary to A β pathology.

Introduction

There is increasing evidence suggesting that the pathogenesis of Alzheimer's disease (AD) is not restricted to amyloid- β (A β) plaques and tau tangles but also includes strong interactions with immunological mechanisms.¹ In line with this, astrocyte reactivity or astrogliosis is a well-known pathological process that is commonly found surrounding A β plaques in the brains of AD patients.² Although the exact role of astrogliosis is not clear, several studies have shown that reactive astrocytes penetrate A β plaques with their processes, possibly in an attempt to isolate the plaques from the surrounding neuropil and phagocytize them.^{3,4} This close relationship between astrocytes and plaques has been further supported by neuropathological reports showing that reactive astrocytes follow the same spatial distribution of A β plaques in the association cortex of AD patients.^{5,6}

In contrast to the association between astrogliosis and A β plaques, the relationship between reactive astrocytes and tau tangles has been less investigated. The few available studies that have assessed this showed that reactive astrocytes also interact with tau, but only in advanced stages of AD by penetrating the extracellular ghost tau tangles.^{7,8} In addition, it has also been found that the association between reactive astrocytes and tau tangles parallels the progression of AD,⁹ however it is not clear whether this association is independent of A β plaques, which are normally present in the brains of patients with AD who have tau tangles.

Thanks to the development of biomarkers to measure astrogliosis, such as the glial fibrillary acidic protein (GFAP), it is now possible to address this question and disentangle the underlying effects of reactive astrocytes on both A β and tau pathology *in vivo*. In particular, the recent assays that allow measuring the concentrations of GFAP in the blood have already demonstrated the potential of plasma GFAP in distinguishing different stages of AD and detecting A β positivity on positron emission tomography (PET).¹⁰⁻¹⁸ However, no study has yet assessed whether plasma GFAP is also associated with tau-PET burden. Moreover, to this date, it is not known whether astrogliosis is independently related to A β or tau pathology, respectively, *in vivo*. This is important for several reasons including the fact that A β and tau pathology are not independent processes, showing a synergistic and complex interaction over the course of AD that may become exacerbated in the presence of other pathological

processes such as astrogliosis.¹⁹ Thus, a better understanding of when reactive astrocytes emerge in the progression of AD and how they relate to the classic AD pathologies is crucial to determine their clinical value as diagnostic or prognostic tools as well as to inform the development of anti-inflammatory drugs in clinical trials.

The aim of this study was to assess whether plasma and cerebrospinal fluid (CSF) GFAP concentrations change across different stages of AD and investigate the independent relationships between these markers with A β and tau pathology measured using ¹⁸F-flutemetamol PET and ¹⁸F-RO948 PET, respectively. Moreover, we compared the performance of GFAP to other glial markers such as soluble triggering receptor expressed on myeloid cells 2 (sTREM2) and chitinase 3-like 1 (YKL-40) to detect A β and tau-PET pathology in order to determine the specificity of our findings. We also evaluated the prognostic ability of baseline GFAP markers to predict longitudinal changes in PET burden and cognitive decline. Finally, we conducted sensitivity analyses in a separate group of patients with non-AD disorders to assess the ability of GFAP markers to detect A β -positivity determined with CSF A β 42/40.

Materials and methods

Participants

This study included 504 individuals from the Swedish BioFINDER-2 cohort (NCT03174938), a prospective study with the aim of developing new biomarkers for the early diagnosis of AD and other neurodegenerative disorders. All participants were recruited at Skåne University Hospital and the Hospital of Ängelholm in Sweden between 2017 and 2020 and included cognitively unimpaired controls, patients with mild cognitive impairment, AD dementia and non-AD disorders.²⁰ Further details regarding the inclusion and exclusion criteria of the subjects included in the different BioFINDER-2 cohorts can be found in the Supplementary Material.

For the purposes of this study, only subjects with baseline plasma and CSF levels of GFAP in addition to other glial markers (YKL-40, sTREM2), ¹⁸F-flutemetamol PET, ¹⁸F-RO948 PET and mini-mental examination scores (MMSE) were included. In addition, a subsample (n = 196) also underwent longitudinal PET imaging and

cognitive assessments (n = 185). Finally, a group of patients with non-AD neurodegenerative disorders without ^{18}F -flutemetamol PET data was also included.

Plasma and cerebrospinal fluid biomarkers

Plasma and CSF samples were collected in the morning during the same visit, with participants nonfasting.²⁰ Blood was collected in six EDTA-plasma tubes and centrifuged (2,000 g, + 4 ° (C) for 10 min. Following centrifugation, plasma was aliquoted into 1.5-ml polypropylene tubes (1 ml plasma in each tube) and stored at -80 °C within 30–60 min of collection. CSF was collected by lumbar puncture and stored at -80°C in polypropylene tubes.¹⁸ The following assays were used to measure the different biomarkers of interest to this study: GFAP Discovery kits for HD-X (Quanterix®, Billerica, MA, USA) for plasma GFAP; NeuroToolKit robust prototype assays (Roche Diagnostics) for CSF GFAP, YKL-40 and sTREM2; and Meso Scale Discovery immunoassays (MSD; Rockville, MD, USA) for CSF A β 42 and CSF A β 40.^{20,21} In all subjects, A β status was established using CSF A β 42/40 levels with a previously established cutoff of 0.0752 defined with mixture modeling²², because CSF A β 42/40 was available in all cases (by study design), whereas A β -PET was only available in non-demented cases.¹⁸

Imaging acquisition and preprocessing

All subjects underwent ^{18}F -flutemetamol PET and ^{18}F -RO948 PET on General Electrics Discovery MI scanners. ^{18}F -flutemetamol PET images were acquired 90 to 110 minutes after injection of 185 MBq ^{18}F -flutemetamol and ^{18}F -RO948 PET images were acquired 70 to 90 minutes after injection of 370 MBq ^{18}F -RO948. Images were reconstructed using VPFX-S (ordered subset expectation maximization combined with corrections for time-of-flight and point spread function).

All ^{18}F -flutemetamol and ^{18}F -RO948 PET images were motion-corrected, time-averaged and coregistered to their corresponding skull stripped, longitudinally preprocessed T1-weighted images. ^{18}F -Flutemetamol scans were normalized using a reference region that included the whole cerebellum, brain stem and eroded subcortical white matter,²³ whereas ^{18}F -RO948 images were normalized by a reference region consisting of the inferior cerebellar gray matter.²⁴

For ^{18}F -flutemetamol images, we calculated the standardized uptake value ratios (SUVR) for a global composite region that included the caudal anterior cingulate, frontal, lateral parietal and lateral temporal gyri.²³ In contrast, for ^{18}F -RO948 PET images we calculated the SUVRs for three composite regions that corresponded to Braak stages I-II (entorhinal cortex), III-IV (parahippocampal, fusiform, amygdala, inferior temporal, middle temporal) and V-VI (posterior cingulate, caudal anterior cingulate, rostral anterior cingulate, precuneus, inferior parietal, superior parietal, insula, supramarginal, lingual, superior temporal, medial orbitofrontal, rostral middle frontal, lateral orbitofrontal, caudal middle frontal, superior frontal, lateral occipital, precentral gyrus, postcentral gyrus and paracentral gyrus).²⁵ Finally, voxel-wise analyses were conducted using the preprocessed ^{18}F -flutemetamol and ^{18}F -RO948 PET images using the statistical parametric mapping software SPM12 (<https://www.fil.ion.ucl.ac.uk/spm/>) after applying a smoothing kernel of 8 mm.

Statistical analyses

Logarithmic or reciprocal transformations were applied to the variables that were not normally distributed. Then, a set of pairwise t-tests was used to compare plasma and CSF GFAP levels between A β -negative cognitively unimpaired (CU), A β -positive CU, A β -positive cognitively impaired (CI), A β -negative CI and non-AD patients, while adjusting for age and sex, and using CSF A β 42/A β 40 to determine the A β status.

To assess the ability of CSF and plasma GFAP markers to predict A β and tau pathology, we used two different approaches: one based on regions of interest (ROI) and the other one based on whole brain voxel-wise analyses. For the first approach, we built separate linear regression models with plasma or CSF GFAP as the dependent variable and global A β , tau stages I-II, tau stages III-IV or tau stages V-VI SUVRs as the outcome, controlling for age and sex. In all models, we verified that the residuals were normally distributed, there was no heteroscedasticity and no multicollinearity. For the second approach, we conducted voxel-wise regression analyses using plasma or CSF GFAP as the dependent variable and the smoothed preprocessed ^{18}F -Flutemetamol or ^{18}F -RO948 PET images as the outcome, including age and sex as covariates. All ROI-based and voxel-wise analyses were carried out in

A β -negative CU, A β -positive CU, all CU subjects, A β -positive CI and A β -negative CI individuals.

For the PET variables showing a significant relationship with plasma and CSF GFAP, we performed three additional analyses. First, we built spline models²⁶ to determine the trajectories of GFAP markers as a function of higher PET burden over the course of AD. Due to previous evidence showing that AD progresses from A β -negative CU to A β -positive CU and finally A β -positive CI,²⁷ we only included these groups in this analysis. Secondly, to determine the impact of astrogliosis on the relationship between the two classical AD hallmarks, we conducted mediation analyses to test whether the relationship between A β -PET and tau-PET burden could be explained by a mediation of GFAP, while controlling for age and sex. The significance of the mediation was assessed by calculating bias-corrected 95% confidence intervals (CIs) using bootstrapping (500 resamples). Thirdly, to establish the area under the curve, sensitivity, specificity and accuracy of GFAP markers in determining an A β -positive status, we calculated receiver-operating curves using a bootstrap procedure with 1000 permutations in the groups who had ¹⁸F-flutemetamol PET data: all CU subjects, all CI subjects and in the whole sample. Since non-AD patients did not have ¹⁸F-flutemetamol scans, the analyses in this group were conducted using CSF A β 42/40 to determine A β -positivity. All receiver-operating curve analyses included YKL-40 and sTREM2 to assess the value of GFAP with respect to other glial markers and their performance was compared using the DeLong test.

Finally, to test whether plasma and CSF GFAP markers were associated with longitudinal changes in cognition and PET burden we applied linear mixed effect models. These models used longitudinal MMSE scores or PET SUVRs as a dependent variable and the GFAP markers, time, age, sex as fixed effects. We also included the interaction between biomarker levels and time (together with the main effects), and random effects for intercepts. Separate models were built for plasma and CSF GFAP, which were ran in all CU subjects, all CI individuals and in the whole sample. The models ran across the entire sample included A β and cognitive status as additional covariates. In addition, to assess whether the effects of GFAP on cognition were independent of A β -PET, longitudinal changes in A β -PET burden were also included as a covariate in a secondary analysis.

Statistical analyses were carried out using SPSS 25.0 (IBM Corp., Armonk, NY, USA), R (version 3.5.1) or SPM12. The analyses conducted in R and SPSS were adjusted for multiple comparisons using false discovery rate (FDR) corrections ($q < 0.05$, two-tailed).²⁸ Similarly, the voxel-wise analyses using PET images were adjusted for multiple comparisons with topological FDR corrections in SPM12 ($p < 0.05$, two-tailed).²⁹

Data availability

Anonymized data will be shared by request from a qualified academic investigator for the sole purpose of replicating procedures and results presented in the article and as long as data transfer is in agreement with EU legislation on the general data protection regulation and decisions by the Ethical Review Board of Sweden and Region Skåne, which should be regulated in a material transfer agreement.

Results

Study participants

In total, 504 participants were included in this study, of which 217 were A β -negative CU, 71 were A β -positive CU, 78 were A β -positive CI (mild cognitive impairment or AD dementia), 63 were A β -negative CI (mild cognitive impairment) and 75 had a non-AD neurodegenerative disorder. There was a moderate correlation between plasma GFAP and CSF GFAP in the entire sample ($r = 0.582$, $p < 0.001$).

Plasma GFAP concentration is increased across different AD stages, whereas CSF GFAP concentration is increased in non-AD disorders

Our findings revealed that plasma GFAP concentration was lowest in A β -negative CI, followed by A β -negative CU, A β -positive CU and A β -positive CI individuals. The group comparisons showed that both A β -positive CU and CI individuals showed elevated plasma GFAP levels compared to the A β -negative CU group ($F_{(2,286)} = 8.33$, $p = 0.004$, $F_{(2,293)} = 12.90$, $p < 0.001$, respectively) and to the A β -negative CI group ($F_{(2,132)} = 18.06$, $p < 0.001$; $F_{(2,139)} = 24.14$, $p < 0.001$, respectively). These findings suggest that plasma GFAP is elevated in individuals with A β pathology.

In contrast to plasma GFAP, CSF GFAP was significantly elevated in patients with a non-AD disorder compared to both A β -negative CU individuals ($F_{(2,290)} = 9.61$, $p = 0.002$) and A β -positive CU individuals ($F_{(2,144)} = 5.71$, $p = 0.018$). These findings suggest that CSF GFAP might be sensitive to different underlying pathological processes unrelated to AD and might be better suited for the detection of non-AD disorders.

Plasma and CSF GFAP concentrations are associated with A β -PET independently of tau-PET burden

To assess whether GFAP biomarkers were associated with the severity of A β deposition, we built linear regression models using global A β -PET SUVR values as the outcome in addition to plasma or CSF GFAP as the predictors. We found that increasing GFAP levels in plasma were associated with greater global A β -PET burden in all CU individuals ($t = 4.24$, $p < 0.001$), A β -negative CU individuals ($t = 2.31$, $p = 0.022$), A β -positive CU individuals ($t = 2.11$, $p = 0.039$) and A β -positive CI individuals ($t = 2.88$, $p = 0.005$). These results were further confirmed by the voxel-wise analyses, which showed that plasma GFAP correlated with higher A β -PET deposition in several neocortical regions in all CU individuals as well as in A β -positive CU individuals. In contrast to plasma GFAP, CSF GFAP only showed a significant association with higher A β -PET deposition in A β -positive CI subjects ($t = 2.92$, $p = 0.005$). To determine whether these results were independent of tau pathology, we repeated all of the above analyses including tau-PET SUVR values of different Braak stage ROIs as covariates. These analyses showed that A β -PET burden was still related to increased plasma GFAP in the same groups (all CU individuals: $t = 4.50$, $p < 0.001$; A β -negative CU individuals: $t = 2.70$, $p = 0.007$; A β -positive CU individuals: $t = 2.32$, $p = 0.024$; A β -positive CI individuals: $t = 2.08$, $p = 0.041$) and to increased CSF GFAP in A β -positive CI individuals ($t = 2.18$, $p = 0.032$), after controlling for tau-PET.

To assess whether the GFAP biomarkers were associated with the severity of tau deposition, we built linear regression models using the tau-PET SUVR values across different Braak stage ROIs as the outcome in addition to plasma or CSF GFAP as the predictors. We found that increasing plasma GFAP levels were only associated with tau-PET burden across Braak stages III-IV and V-VI in A β -positive CI individuals

(III-IV: $t = 2.86$, $p = 0.006$; V-VI: $t = 2.97$, $p = 0.004$). However, these associations lost their significance after including global A β -PET as a covariate (III-IV: $t = 1.60$, $p = 0.114$; V-VI: $t = 2.00$, $p = 0.050$), indicating that they were not independent of A β pathology.

Plasma GFAP concentration shows early increases with A β -PET burden

To determine the trajectories of plasma and CSF GFAP concentrations over the course of AD, we fitted spline models for these markers using global A β -PET SUVR as a proxy for time. These analyses did not include non-AD patients or A β -negative CI individuals since they are not considered to be part of the AD spectrum.²⁷ The results of these analyses revealed that both models were significant, with the one having plasma GFAP as a predictor showing a better model fit (r^2 : 0.21, $p < 0.001$) compared to the one with CSF GFAP (r^2 : 0.14, $p < 0.001$). The trajectories of these models revealed initial increases for both plasma GFAP and CSF GFAP, which continued rising after reaching the threshold for A β -PET positivity and then later came to a plateau. Despite showing similar trajectories, when we compared the splines of plasma and CSF GFAP, we could observe that plasma GFAP showed steeper initial increases, overcoming CSF GFAP levels even before A β -PET positivity. These results indicate that plasma GFAP might exhibit greater changes with increasing A β pathology during AD compared to CSF GFAP.

Plasma GFAP may partially mediate the relationship between A β -PET and tau-PET over the course of AD

To further investigate the role of astrocytosis in relation to the classical AD pathologies over the course of the disease we conducted mediation analyses in all CU subjects as well as A β -positive CI individuals. These analyses showed that plasma GFAP mediated the effect between global A β -PET and both tau-PET stages I-II (-0.027, 95% CI: 0.00 to -0.056, $P = 0.035$) and stages III-IV (-0.027, 95% CI: -0.056 to -0.01, $P = 0.010$) in CU individuals. Moreover, plasma GFAP also mediated the effects between global A β -PET and tau-PET stages V-VI (0.131, 95% CI: 0.00 to 0.33, $P = 0.046$) in CI individuals. These findings suggest that astrocytosis secondary to A β accumulation might be one of the factors contributing to tau accumulation in AD.

Plasma GFAP identifies an A β -positive status more accurately than CSF GFAP and other glial markers

To determine the performance of the glial biomarkers (GFAP, YKL-40 and sTREM2) to detect A β positivity, we conducted receiver-operating curve analyses in the whole sample, all CU individuals, all CI individuals as well as non-AD patients, regardless of their A β status, which were defined using A β -PET or CSF A β 42/40 (non-AD patients only). These analyses showed that plasma GFAP showed an area under the curve of 0.761 in the whole sample, 0.754 in all CU individuals, 0.779 in all CI individuals and 0.755 in non-AD patients. These performances were significantly better than the ones achieved by CSF GFAP ($Z = 2.68$, $p = 0.007$), CSF sTREM2 ($Z = 3.31$, $p < 0.001$) and almost CSF YKL-40 ($Z = 1.77$, $p = 0.077$) in the whole sample; by CSF GFAP ($Z = 2.24$, $p = 0.024$) in CU individuals; by CSF GFAP ($Z = 2.24$, $p = 0.025$), CSF sTREM2 ($Z = 3.08$, $p = 0.002$) and CSF YKL-40 ($Z = 2.72$, $p = 0.006$) in CI individuals; and by CSF YKL-40 ($Z = 2.42$, $p = 0.016$) and almost CSF sTREM2 ($Z = 1.80$, $p = 0.072$) in non-AD patients. Altogether, these analyses indicate that plasma GFAP can detect an A β positive status more accurately than the other glial markers.

Plasma GFAP concentration is associated with longitudinal A β accumulation determined by PET

For the subsample that underwent longitudinal A β -PET ($n = 196$, number of visits: $M = 1.5$, $IQR = 1$; follow-up time: $M = 1.7$ years, $IQR = 0.3$), we used linear mixed models to evaluate whether the GFAP markers were also associated with A β changes over time in a neocortical composite region. These analyses showed that plasma GFAP predicted longitudinal A β deposition in the whole sample ($t = 2.888$, $p = 0.004$), whereas CSF GFAP did not ($t = 1.478$, $p = 0.141$), after controlling for age, sex, baseline A β status and presence of cognitive impairment. Notably, these analyses remained significant after adjusting also for tau-PET burden ($t = 2.905$, $p = 0.004$), indicating they were independent of tau pathology. However, no significant results when the analyses were conducted in the CU and CI groups separately.

Plasma and CSF GFAP concentrations are associated with longitudinal cognitive decline

For the subsample that underwent longitudinal cognitive assessment ($n = 185$, number of visits: $M = 2$, $IQR = 2$; follow-up time: $M = 1.9$ years, $IQR = 0.7$), we also used linear mixed models to evaluate whether the GFAP markers were associated with cognitive changes over time. These analyses showed that both plasma GFAP and CSF GFAP predicted cognitive decline in the whole cohort, even after adjusting for longitudinal A β -PET changes (plasma GFAP: $t = -3.303$, $p = 0.001$; CSF GFAP: $t = -2.485$, $p = 0.014$). These results suggest that, in addition to being a marker of A β pathology, astrocytosis could have an independent negative impact on longitudinal cognition. No significant results were found when the analyses were conducted in the CU and CI groups separately.

Discussion

Although emerging evidence suggests that inflammation has a causal role in AD,¹¹⁻¹⁸ the detection of inflammatory markers has not yet been established as a valuable method for the early diagnosis and monitoring of AD patients.¹ Our findings show that plasma GFAP holds great potential as an early and specific marker of A β deposition even during the earliest stages of AD. Moreover, we found that plasma GFAP was a prognostic marker of both longitudinal A β accumulation and cognitive decline and a mediator of the effects of A β -PET on tau-PET burden. In light of the invasiveness of lumbar punctures for CSF and the high cost of PET imaging, our findings suggest that plasma GFAP could become a widely available screening tool to identify astrocytosis in early AD. Moreover, it could also be used to evaluate the effects of anti-A β therapies on glial activation as well as to better understand the role of astrocytosis over the course of AD.

Activated glia in the form of reactive astrocytes is one of the most prominent neuropathological features of AD, being normally found surrounding A β plaques in postmortem brain tissue.³⁰ The role of these reactive astrocytes has been debated over the past few years, with some studies suggesting they are part of an endogenous defensive mechanism to eliminate the plaques, whereas others defend that their persistent activation induces a toxic inflammatory process that contributes to worsening AD progression.³¹ Regardless of their role, several studies have used

biomarkers such as GFAP to measure astrocytosis *in vivo* in the CSF or more recently in the blood plasma. Although studies assessing GFAP in CSF have reported somewhat inconsistent findings across different stages of AD,^{32,33} recent studies on plasma GFAP showed more promising results. In particular, elevated plasma GFAP was recently found in subjects with subjective cognitive decline, mild cognitive impairment and AD dementia with a positive A β -PET scan.¹⁵ In addition, an association between longitudinal plasma GFAP and conversion to dementia was also found in a prospective clinical cohort, highlighting its potential value as a prognostic tool.³⁴ In the current study, we extend these previous findings by showing that plasma GFAP is not only elevated in subjects with A β pathology but also correlates with continuous A β -PET values, even in individuals with normal CSF A β 42/40 levels. Interestingly, when we conducted our analyses at the voxel-level we found that elevated plasma GFAP was associated with higher A β -PET burden in neocortical regions where A β accumulation is normally observed in AD both in all CU as well as A β -positive CU individuals. This result is in agreement with previous studies showing that astrocytes show dynamic changes over the course of AD, with reactive astrocytes being more prominent in earlier disease stages.³¹ In addition, this result is also in line with a previous report showing that reactive astrocytes follow the same spatial distribution of A β plaques in the association cortex of AD patients.⁵

Compared to A β plaques, the potential associations between reactive astrocytes and neurofibrillary tangles have been much less studied. Immunohistochemical and electron microscopy studies have shown that reactive astrocytes can also penetrate with their processes the extracellular ghost tangles in the midst of the neuropil in advanced AD.^{7,8} Moreover, in another study, a significant linear rise of astrocytosis in the vicinity of neurofibrillary tangles was found with increasing AD progression, although this relationship was weaker than the one observed between astrocytosis and A β plaques.³⁵ Finally, in a study using autoradiography, tau deposits were observed in similar brain areas as activated astrocytes, supporting a pathological interconnection.³⁶ To our knowledge, no studies have assessed whether astrocytic markers such as plasma and CSF GFAP are associated with *in vivo regional* tau-PET pathology in the course of AD. Here, we show that greater tau-PET signal in middle and late Braak stages was associated with increasing plasma GFAP in A β -positive CI individuals. However, when these associations were adjusted for A β -PET burden their

significance was lost, in contrast to the correlations between plasma GFAP and A β -PET, which remained unchanged after adjusting for tau-PET signal. These findings indicate that astrogliosis measured by initial increases in GFAP is specifically associated with A β pathology, challenging previous assumptions that both A β and tau pathology can trigger reactive astrocytes in AD.^{6,35}

In contrast to plasma GFAP, CSF GFAP was only associated with A β pathology in CI individuals, showed less steep increases with increasing A β -PET burden in the spline models, and was significantly elevated in patients with non-AD disorders. These findings suggest that plasma and CSF GFAP might be measuring partially different pathological processes, with the former being more closely related to abnormal A β accumulation due to AD, whereas the latter also incorporating other neuroinflammatory changes unrelated to A β pathology. Moreover, together with sTREM2 and YKL-40, CSF GFAP showed a lower sensitivity and specificity in detecting A β -positivity compared to plasma GFAP. In fact, the ability of plasma GFAP to identify A β -PET or CSF A β 42/40 pathology was quite consistent across the whole sample, CU individuals, CI individuals and non-AD disorders with an area under the curve above 0.75 in all cases, which is similar to the values obtained in a previous study using the same biomarker.¹⁵ These results suggest that plasma GFAP can be reliably used to detect A β -positivity across different disease stages as well as non-AD disorders. The differences between plasma and CSF GFAP could also be related to different clearance pathways of the molecule into the biofluids. For instance, astrocytic end-feet projections to the neurovascular unit may provide a direct clearance pathway of the molecule into the bloodstream, and there may also be relationships with vascular amyloid pathology, which is common in AD³⁷.

Regarding the prognostic value of GFAP, we found that both CSF and plasma predicted global cognitive decline to the same degree, even after adjusting for changes in A β -PET accumulation. It has been previously suggested that, although glial responses are initially triggered by A β burden, they can become progressively independent of A β with disease progression and contribute to neurodegenerative and cognitive changes.³⁵ Our findings seem to confirm this assumption as the associations between plasma GFAP and cognitive decline were still significant after adjusting for A β -PET burden, indicating that astrogliosis has a negative impact on cognition that goes beyond its link to A β pathology. This suggests that astrogliosis may play a role

in promoting cognitive deterioration in AD and that therapies targeting this neuroinflammatory process could at least partially ameliorate cognitive symptoms. In addition, regarding longitudinal A β accumulation, we found that plasma GFAP was a better predictor of A β -PET burden over time, even after controlling for tau-PET signals, suggesting that plasma GFAP is a more sensitive tool to identify not only baseline but also future A β pathology. Finally, our mediation analyses revealed that plasma GFAP also mediated the effects between A β -PET and tau-PET in CU and CI individuals in a stage-dependent manner, indicating that astrocytosis might be contributing to tau accumulation, although this effect is not independent of A β pathology. These findings could have important implications for current treatments in AD and suggest that a combination of anti-amyloid therapies with anti-inflammatory treatments could potentially reduce the formation of tau aggregates.

Our study has several strengths, including the large number of participants with several glial biomarkers and longitudinal A β -PET, longitudinal tau-PET and global cognition. However, a few limitations should also be recognized such as the fact that we did not have serial longitudinal measures of plasma and CSF GFAP, which would have been useful to determine their trajectories over the course of AD and determine their potential clinical value as longitudinal monitoring tools. In addition, plasma GFAP and CSF GFAP were also measured using different platforms, Simoa and NeuroToolKit, respectively. At the time of the study, there was only one follow-up available for A β -PET and two follow-ups available for cognition within a period of approximately two years. This may have limited our ability to detect effects that were stronger enough to reach significance in the CU and CI groups separately since a longer time period may be required to observe more prominent A β -PET and cognitive changes. Finally, the inclusion of a PET imaging tracer such as ^{11}C -deuterium-l-deprenyl³⁸ would have been interesting to include to assess the relationship between plasma GFAP and regional brain astrocytosis.

In summary, here we show that baseline plasma GFAP seems to be a very early marker of astrocytosis associated with A β pathology suggesting it can be used to detect baseline A β -positivity and predict future A β accumulation and cognitive decline. In addition, contrary to previous assumptions, astrocytosis measured with GFAP was not associated with tau pathology after controlling for A β , indicating it is not only an early but also a quite specific marker for A β pathology. Although current

models of AD have adopted a neurocentric view that starts with A β accumulation, followed by tau deposition and neurodegeneration, it is well known that neurons cannot function properly without the proper support of glial cells such as astrocytes.³¹ Thus, our findings highlight the importance of including astroglial markers in the cascade of pathological changes occurring in AD, particularly plasma GFAP, which could potentially be used as a non-invasive tool to evaluate the effects of anti-A β drugs or anti-inflammatory treatments on astrocytosis in clinical trials.

Funding

The Swedish BioFINDER-2 study was supported by the Swedish Research Council (2016-00906 and 2018-02052), the Knut and Alice Wallenberg foundation (2017-0383), the Marianne and Marcus Wallenberg foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF-939932), the Swedish Brain Foundation (FO2019-0326), The Parkinson foundation of Sweden (1280/20), the Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2020-0314) and the Swedish federal government under the ALF agreement (2018-Projekt0279). The precursor of 18F-flutemetamol was sponsored by GE Healthcare. The precursor of 18F-RO948 was provided by Roche. J.B.P. is supported by grants from the Swedish Research Council (#2018-02201), The Center for Medical Innovation (#20200695), a Senior Researcher Position grant at Karolinska Institute, Gamla Tjänarinnor, and Stohnes. K.B. is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), and European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931) and the UK Dementia Research Institute at UCL.

Competing interests

S.P. has served at scientific advisory boards for Geras Solutions and Hoffmann-La Roche. H.Z. has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. K.B. has served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche. The rest of authors do not report any disclosures.

References

1. Heneka MT, Carson MJ, El Khoury J *et al.* Neuroinflammation in Alzheimer's disease. *Lancet Neurol.* 2015;14:388-405.
2. Osborn LM, Kamphuis W, Wadman WJ, Hol EM. Astrogliosis: an integral player in the pathogenesis of Alzheimer's disease. *Prog Neurobiol.* 2016;144:121-41.
3. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. *J Neuroimmunology.* 1989;24:173-82.
4. Frost GR, Li YM. The role of astrocytes in amyloid production and Alzheimer's disease. *Open Biol.* 2017;7:170228.
5. Beach TG, McGeer EG. Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer's disease visual cortex. *Brain Res.* 1988;463:357-61.
6. Perez-Nievas BG, Serrano-Pozo A. Deciphering the astrocyte reaction in Alzheimer's disease. *Front Aging Neurosci.* 2018;10:114.

7. Ikeda K, Haga C, Akiyama H, Kase K, Iritani S. Coexistence of paired helical filaments and glial filaments in astrocytic processes within ghost tangles. *Neurosci Lett*. 1992;148:126-8.
8. Ikeda K, Haga C, Oyanagi S, Iritani S, Kosaka K. Ultrastructural and immunohistochemical study of degenerate neurite-bearing ghost tangles. *J Neurol*. 1992;239:191-4.
9. Simpson JE, Ince PG, Lace G *et al*. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. *Neurobiol Aging*. 2010;31:578-90.
10. Rajan KB, Aggarwal NT, McAninch EA *et al*. Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study. *Ann Neurol*. 2020;88:1065-76.
11. Oeckl P, Halbgebauer S, Anderl-Straub S *et al*. Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment. *J Alzh Dis*. 2019;67:481-8.
12. Elahi FM, Casaletto KB, La Joie R *et al*. Plasma biomarkers of astrocytic and neuronal dysfunction in early-and late-onset Alzheimer's disease. *Alzheimers & Dem*. 2019;16:681-95.
13. Thijssen EH, Verberk IM, Stoops E, Boxer AL, Teunissen CE. Amyloid, pTau, NfL, and GFAP as biomarkers for Alzheimer's disease: Clinical study results of AD blood biomarkers. *Alzheimers & Dem*. 2020;16:e038179.
14. Asken BM, Elahi FM, La Joie R *et al*. Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage. *J Alzh Dis*. 2020; In press.
15. Chatterjee P, Pedrini S, Stoops E *et al*. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. *Trans Psych*. 2021;11:27.
16. Cicognola C, Janelidze S, Hertze J *et al*. Plasma Glial Fibrillary Acidic Protein Detects Alzheimer Pathology and Predicts Future Conversion to Alzheimer Dementia in Patients With Mild Cognitive Impairment. *Alzheimers Res Ther* 2021; In press.

17. Verberk IM, Thijssen E, Koelewijn J et al. Combination of plasma amyloid beta (1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. *Alzheimers Res Ther* 2020;12:1-4.
18. Simrén J, Leuzy A, Karikari TK et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. *Alzheimers & Dem* 2021; In press.
19. Busche MA, Hyman BT. Synergy between amyloid- β and tau in Alzheimer's disease. *Nat Neurosci*. 2020;23:1183-93.
20. Palmqvist S, Janelidze S, Quiroz YT *et al*. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. *JAMA*. 2020;324:772-81.
21. Palmqvist S, Janelidze S, Stomrud E *et al*. Performance of fully automated plasma assays as screening tests for alzheimer disease-related b-amyloid status. *JAMA Neurol*. 2019;76:1060-9.
22. Bertens D, Tijms BM, Scheltens P, Teunissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid beta-amyloid 1-42 cutoffs in a large memory clinic population. *Alzheimers Res Ther*. 2017;9:8.
23. Landau SM, Fero A, Baker SL et al. Measurement of longitudinal β -amyloid change with 18F-florbetapir PET and standardized uptake value ratios. *J Nucl Med*. 2015;56:567-74.
24. Ossenkoppele R, Rabinovici GD, Smith R *et al*. Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. *JAMA*. 2018;320:1151-62.
25. Cho H, Choi JY, Hwang MS *et al*. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. *Ann Neurol*. 2016;80:247-58.
26. Palmqvist S, Insel PS, Stomrud E *et al*. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. *EMBO Mol Med*. 2019;11:e11170.
27. Jack Jr CR, Knopman DS, Jagust WJ *et al*. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol*. 2013;12:207-16.

28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J Royal Stat Soc Series B*. 1995;57:289-300.
29. Chumbley J, Worsley K, Flandin G, Friston K. Topological FDR for neuroimaging. *Neuroimage*. 2010;49:3057-964.
30. Medeiros R, LaFerla FM. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. *Exp Neurol*. 2013;239:133-8.
31. Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER. Astrocyte biomarkers in Alzheimer's disease. *Trends Mol Med*. 2019;25:77-95.
32. Olsson B, Lautner R, Andreasson U *et al*. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. *Lancet Neurol*. 2016;15:673-84.
33. Van Hulle C, Jonaitis EM, Betthausen TJ *et al*. An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. *Alzheimers Dement*. 2020; In press.
34. Verberk IM, Laarhuis MB, van den Bosch KA *et al*. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. *Lancet Healthy Long*. 2021;2:e87-95.
35. Serrano-Pozo A, Mielke ML, Gómez-Isla T *et al*. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. *Am J Pathol*. 2011;179:1373-84.
36. Lemoine L, Saint-Aubert L, Nennesmo I, Gillberg PG, Nordberg A. Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by 3 H-THK5117 and 3 H-deprenyl autoradiography. *Sci Rep*. 2017;7:1-1.
37. Bourassa P, Tremblay C, Schneider JA, Bennett DA, Calon F. Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer's disease. *Acta Neuropathol*. 2019;137:801-23.

38. Rodriguez-Vieitez E, Carter SF, Chiotis K *et al.* Comparison of early-phase 11C-deuterium-l-deprenyl and 11C-Pittsburgh compound B PET for assessing brain perfusion in Alzheimer disease. *J Nucl Med.* 2016;57:1071-7.